NASDAQ · NEO
Healthcare · Medical - Diagnostics & Research
$16.65
Down-$0.60 (-3.48%)
Updated Oct 17, 2026, 9:33 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NEO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
NEO closed at $16.65 after 21 trading sessions, down 16.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $17.24 | $17.45 | $16.44 | $16.65 | 2.31M |
| Oct 15, 2026 | $17.00 | $17.335 | $16.61 | $17.25 | 1.32M |
| Oct 14, 2026 | $16.49 | $17.25 | $16.445 | $16.88 | 1.62M |
| Oct 13, 2026 | $16.30 | $16.98 | $15.9796 | $16.66 | 2.24M |
| Oct 12, 2026 | $16.35 | $16.35 | $15.86 | $16.20 | 1.18M |
| Oct 9, 2026 | $16.02 | $16.655 | $16.00 | $16.35 | 1.39M |
| Oct 8, 2026 | $15.72 | $16.09 | $15.41 | $16.02 | 3.52M |
| Oct 7, 2026 | $16.36 | $16.64 | $15.8801 | $15.97 | 3.19M |
| Oct 6, 2026 | $20.00 | $20.15 | $16.47 | $16.505 | 5.1M |
| Oct 5, 2026 | $18.48 | $19.13 | $18.28 | $19.13 | 2.06M |
| Oct 2, 2026 | $17.99 | $18.69 | $17.94 | $18.47 | 2.3M |
| Oct 1, 2026 | $18.18 | $18.76 | $17.74 | $17.78 | 2.47M |
| Sep 30, 2026 | $18.76 | $18.965 | $18.28 | $18.36 | 2.47M |
| Sep 29, 2026 | $19.30 | $19.748 | $18.58 | $18.74 | 2.7M |
| Sep 28, 2026 | $19.02 | $19.59 | $19.005 | $19.29 | 1.3M |
| Sep 25, 2026 | $19.56 | $19.75 | $18.87 | $19.33 | 2.02M |
| Sep 24, 2026 | $18.47 | $19.73 | $18.40 | $19.56 | 2.95M |
| Sep 23, 2026 | $18.69 | $19.079 | $18.27 | $18.36 | 2.91M |
| Sep 22, 2026 | $19.28 | $19.60 | $18.83 | $18.89 | 4M |
| Sep 21, 2026 | $19.92 | $20.0499 | $19.28 | $19.41 | 1.44M |
| Sep 18, 2026 | $19.91 | $20.025 | $19.395 | $19.91 | 4.4M |
The latest Smart Investors Daily articles mentioning NEO.
Company
Market Activity
Research & News
NEO research
Company profile and research snapshot.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | BTIG | Buy | — |
| Oct 6, 2026 | StoneX | Buy | — |
| Oct 6, 2026 | Needham | Buy | — |
| Jul 29, 2026 | Needham | Buy | — |
| Jul 24, 2026 | Benchmark | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 14, 2026
FORT MYERS, Fla., October 14, 2026--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.
Yahoo · Oct 13, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
SeekingAlpha · Oct 12, 2026
BillionToOne (BLLN) stock analysis: QCT-driven diagnostics, 70% GMS and 38% growth vs peers. Read here for a detailed investment analysis.
Yahoo · Oct 6, 2026
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.6% in the pre-market session after the company announced an executive succession plan alongside preliminary updates that pointed to higher full-year guidance.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEO.
